Table 2 Clinical characters of HCC patients in the TCGA training cohort and GSE14520 validation cohorts

TCGA (training set)

Age

1.24 (0.88–1.76)

0.23

1.14 (0.76–1.70)

0.53

Gender

1.22 (0.86–1.73)

0.28

1.23 (0.85–1.78)

0.072

Race

0.87 (0.72–1.05)

0.14

1.22 (0.94–1.58)

0.14

Pathologic_stage

1.64 (1.34–2.00)

1.81E-06

1.14 (0.50–2.62)

0.75

Pathology_T_stage

1.61 (1.36–1.91)

2.94E-08

1.46 (0.66–3.21)

0.35

Pathology_N_stage

1.25 (1.04–1.50)

0.017

1.07 (0.81–1.42)

0.63

Pathology_M_stage

1.29 (1.07–1.55)

0.0068

1.42 (1.06–1.89)

0.018

Risk score

1.89 (1.34–2.69)

3.41E-04

1.81 (1.21–2.70)

0.0037

GSE14520 (validation set)

Age

0.80 (0.53–1.19)

0.26

1.05 (0.67–1.66)

0.82

Gender

0.54 (0.26–1.11)

0.093

0.81 (0.39–1.71)

0.58

TNM_staging

2.34 (1.77–3.09)

2.18E-09

1.42 (0.98–2.06)

0.067

BCLC_staging

2.22 (1.75–2.81)

3.34E-11

1.36 (0.91–2.03)

0.13

CLIP_staging

1.92 (1.55–2.38)

1.65E-09

1.45 (0.93–2.24)

0.099

AFP

1.69 (1.13–2.53)

0.011

0.84 (0.43–1.64)

0.61

Risk score

1.56 (1.04–2.33)

0.031

1.27 (0.82–1.97)

0.29